Farhad Ravandi Selected Research

Radiotherapy

10/2022	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
1/2020	Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
10/2014	A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
2/2012	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Farhad Ravandi Research Topics

Disease

253	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 02/2004
89	Neoplasms (Cancer) 03/2024 - 02/2005
83	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2024 - 02/2006
81	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2024 - 06/2006
66	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2024 - 11/2002
63	Leukemia 12/2023 - 11/2002
59	Philadelphia Chromosome 04/2024 - 09/2006
35	Acute Promyelocytic Leukemia 02/2024 - 02/2004
22	Infections 11/2023 - 02/2005
21	Residual Neoplasm 12/2022 - 01/2009
17	Hairy Cell Leukemia 05/2024 - 09/2005
15	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 03/2024 - 10/2006
13	Blast Crisis (Blast Phase) 01/2023 - 02/2007
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2005
13	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 02/2003
12	Exanthema (Rash) 11/2023 - 06/2009
11	Thrombocytopenia (Thrombopenia) 01/2023 - 07/2010
11	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 09/2006
10	Neutropenia 04/2024 - 05/2004
10	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 06/2011
10	Pathologic Complete Response 12/2020 - 09/2010
8	Disease Progression 05/2024 - 10/2012
8	Hypertension (High Blood Pressure) 01/2023 - 01/2011
7	Lymphoma (Lymphomas) 01/2021 - 04/2006
6	Anemia 01/2023 - 07/2010
6	Fatigue 12/2021 - 05/2006
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 03/2003
6	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020 - 08/2013
5	Nausea 11/2023 - 02/2015
5	Hemorrhage 01/2023 - 06/2009
5	Diarrhea 01/2019 - 10/2008
4	Leukocytosis (Pleocytosis) 01/2022 - 09/2008
4	Hyperbilirubinemia 01/2022 - 10/2008
4	Pneumonia (Pneumonitis) 01/2022 - 07/2012

Drug/Important Bio-Agent (IBA)

55	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023 - 11/2005
53	Tyrosine Kinase InhibitorsIBA 01/2023 - 05/2009
45	venetoclaxIBA 04/2024 - 01/2018
44	Decitabine FDA Link 04/2024 - 03/2003
34	Imatinib Mesylate (Gleevec)FDA Link 11/2019 - 02/2003
28	Azacitidine (5 Azacytidine)FDA Link 11/2023 - 10/2007
24	Dasatinib (BMS 354825)FDA Link 04/2024 - 08/2008
22	Core Binding Factors (Core-Binding Factor)IBA 01/2023 - 12/2008
19	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 10/2008
18	Arsenic Trioxide (Trisenox)FDA Link 02/2024 - 11/2002
18	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2002
17	ponatinibIBA 04/2024 - 04/2015
17	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2024 - 02/2004
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021 - 03/2003
16	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 02/2007
16	Dexamethasone (Maxidex)FDA LinkGeneric 11/2021 - 10/2008
16	Monoclonal AntibodiesIBA 01/2021 - 09/2005
16	Clofarabine (Clolar)FDA Link 01/2021 - 07/2006
15	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2011
14	blinatumomabIBA 12/2023 - 01/2018
14	Inotuzumab OzogamicinIBA 12/2023 - 06/2013
13	Rituximab (Mabthera)FDA Link 05/2024 - 08/2010
13	Phosphotransferases (Kinase)IBA 01/2023 - 11/2002
13	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 10/2008
12	Cladribine FDA LinkGeneric 05/2024 - 06/2006
12	Sorafenib (BAY 43-9006)FDA Link 11/2023 - 12/2008
11	fludarabineIBA 01/2023 - 12/2008
11	NucleosidesIBA 12/2015 - 09/2005
9	Transaminases (Aminotransferases)IBA 01/2023 - 10/2008
9	Gemtuzumab (Mylotarg)FDA Link 11/2022 - 02/2009
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 08/2013
8	BilirubinIBA 12/2023 - 04/2012
8	Lenalidomide (CC 5013)FDA Link 10/2022 - 10/2009
8	purineIBA 05/2022 - 09/2005
8	Alemtuzumab (Campath)FDA Link 11/2009 - 02/2005
7	NucleophosminIBA 01/2023 - 01/2009
7	AnthracyclinesIBA 05/2022 - 07/2010
7	ruxolitinibIBA 11/2021 - 08/2011
7	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 03/2014
7	Pentostatin (Nipent)FDA LinkGeneric 01/2020 - 01/2006
7	Prednisone (Sone)FDA LinkGeneric 12/2018 - 10/2009
6	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023 - 10/2013
6	CreatinineIBA 12/2023 - 01/2010
6	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023 - 12/2008
6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2023 - 01/2011
6	Tyrosine (L-Tyrosine)FDA Link 10/2019 - 01/2008
6	vosaroxinIBA 11/2018 - 02/2015
6	nilotinib FDA Link 01/2018 - 08/2008
5	EnzymesIBA 01/2023 - 08/2010
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 12/2011
5	Methotrexate (Mexate)FDA LinkGeneric 02/2016 - 04/2007
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 11/2010

Therapy/Procedure

222	Therapeutics 04/2024 - 02/2003
108	Drug Therapy (Chemotherapy) 05/2024 - 02/2006
21	Stem Cell Transplantation 01/2023 - 02/2005
16	Induction Chemotherapy 01/2022 - 12/2010
14	Salvage Therapy 01/2023 - 07/2007
13	Hematopoietic Stem Cell Transplantation 01/2023 - 05/2006
6	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 11/2010
5	Cell Transplantation 11/2022 - 01/2007
5	Immunotherapy 01/2022 - 06/2011
5	Transplantation 01/2021 - 11/2006
4	Consolidation Chemotherapy 12/2022 - 01/2018
4	Remission Induction 10/2022 - 01/2010
4	Radiotherapy 10/2022 - 02/2012